Reduced Risk of Prostate Cancer With 5alpha-Reductase Inhibitors
Menée en Suède à partir de données portant sur 333 820 participants, cette étude prospective évalue l'association entre une utilisation d'inhibiteurs de la 5-alpha-réductase pour traiter des symptômes des voies urinaires basses et le risque de cancer de la prostate de haut grade (score de Gleason de 8 à 10)
Prostate cancer (PCA) and lower urinary tract symptoms (LUTS) associated with aging and benign prostatic hyperplasia are ubiquitous in aging men. PCA has a high prevalence, causes considerable morbidity when metastatic, and is the third most common cause of cancer death in men (1). LUTS adversely affects quality of life and may result in recurrent infections and urinary retention, leading to morbidity and mortality among older men. ... A seminal clinical trial compared the efficacy of two medications to control symptoms and prevent progression of LUTS. In this study, while alpha blockade with doxazosin resulted in more improvement in urinary symptoms, inhibition of 5
α-reductase with finasteride was found to not only...